What is 'Acting In Concert'

Acting in concert is a slang term for when parties undertake identical investment actions to achieve the same goal. Acting in concert requires the cooperation of people or corporations to make the same transactions based on a previous arrangement.

BREAKING DOWN 'Acting In Concert'

The issue of acting in concert is often examined in the world of acquisitions. Investors are usually required to declare any takeover intentions or place a tender offer after acquiring a specific percentage of shares in a company. However, some may try to spread the ownership percentage among friendly parties in an attempt to avoid declaring or bidding. Regulators have determined that if people are acting in concert and the sum of ownership exceeds the specified percentage, the group must declare its intentions. If investors believe their interests were harmed by others acting in concert, they may sue. This happened in the following high-profile case that began in 2014.

Example of Acting in Concert

It was alleged that Bill Ackman, leader of hedge fund Pershing Square Capital Management, and Michael Pearson, CEO of Valeant Pharmaceuticals International, acted in concert to try to purchase Botox maker Allergan Inc. in 2014. Ackman's fund independently accumulated a large position in Allergan and then teamed up with Valeant to bid for Allergan. Allergan, which did not want to be acquired by Valeant, and two state pension plans sued Ackman and Valeant for violating securiities laws on the grounds of insider trading. In the meantime, Allergan began putting together a deal with Actavis Plc to thwart efforts by Ackman and Valeant.

Actavis and Allergan did end up consummating a deal in March 2015, which delivered a huge investment gain to Ackman. He squandered those gains and more, however, after he reinvested the proceeds into Valeant, whose enormous debt levels and alleged fraudulent accounting practices sent investors fleeing. Valeant stock had soared over $250 per share in July 2015; when Ackman sold his shares in March 2017, they were trading at around $11 per share. Adding insult to injury, Ackman was forced to finally settle the outstanding lawsuit against him, paying $193.75 million. Valeant agreed to pay $96.25 million, the other portion of the $290 million total settlement. Acting in concert with Valeant was a painful experience for Bill and Michael.

RELATED TERMS
  1. Clandestine Takeover

    Clandestine takeover is an attempt to gain control over a company ...
  2. Creeping Tender Offer

    A creeping tender offer is a takeover strategy involving the ...
  3. Activist Investor

    An activist investor is an individual or group that invests in ...
  4. Blanket Additional Insured Endorsement

    A blanket additional insured endorsement automatically provides ...
  5. Forced Selling (Forced Liquidation)

    Forced selling or forced liquidation usually entails the involuntary ...
  6. Advance Corporation Tax - ACT

    Advance corporation tax is the prepayment of corporate taxes ...
Related Articles
  1. Investing

    Ackman's Valeant Holdings Lost Pershing $7.7 Million a Day

    If his final shares were worth $200M, how did the losses come to $4B?
  2. Investing

    Ackman's Pershing Sq. Dumps 3.4M Valeant Shares at a Loss

    This is not a test. This time he's possibly dumping the shares for real.
  3. Investing

    Valeant turns First Profit in Six Quarters

    Is it too little, too late for Valeant investors?
  4. Insights

    Valeant's Meltdown in 2016: A Year In Review

    The embattled drug company, whose year was marred by lawsuits and controversy, has time to change its course
  5. Investing

    Valeant Stock Rises 5% on Possible Asset Sales

    Valeant, which has more than $30 billion in debt on its books, needs to raise cash to service its obligations.
  6. Investing

    4 Lessons Valeant Can Teach Investors (VRX)

    Learn about the storied tumble of Valeant Pharmaceuticals Inc. and the subsequent effect on institutional and individual investors.
  7. Investing

    Will Valeant Stock Remain Toxic in 2017?

    After losing some 86% of its value last year, Valeant doesn't have to be extraordinary in 2017 to have a bounce-back year.
  8. Investing

    How Valeant’s Scandal Has Impacted Its Stock Price (VRX)

    Since its peak price on August 5, 2015, Valeant’s shares have lost 86% of their value.
  9. Investing

    Can Donald Trump Make Valeant Stock Great Again? (VRX, XLV)

    Shares of Valeant have been under heavy selling pressure over the past month, plunging as much as 27% from around $22 to Friday's close of $15.45.
  10. Insights

    Valeant Files Late Annual Report, Restates Results (VRX)

    Valeant Pharmaceuticals filed its overdue 10-K form with the SEC Friday, restating revenues and profits for 2014 and much of 2015 and, it says in the filing, clearing up the risk of defaulting ...
Trading Center